Navigation Links
Adeona Executes Agreement to Initiate Phase IIb Clinical Trial of Proprietary Zinc-Based Therapy in Lou Gehrig's Disease (ALS)
Date:6/23/2011

ANN ARBOR, Mich., June 23, 2011 /PRNewswire/ -- Adeona Pharmaceuticals, Inc. (NYSE Amex: AEN), a developer of innovative medicines for serious central nervous system diseases, announced today that it has expanded its pipeline of proprietary zinc-based therapies to include a planned Phase IIb clinical trial of patients suffering from amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's Disease. Preparations are underway to evaluate the safety and efficacy of the Company's proprietary drug candidates, AEN-100, a gastroretentive, sustained-release zinc-based tablet, and AEN-200, a copper tablet, in a multi-center, double-blind, placebo-controlled clinical trial in ALS patients intended to be conducted under an Investigational New Drug (IND) application. Adeona will provide the study medications and fund the clinical trial, which will be conducted by the neurology team at the PNA Center for Neurological Research in collaboration with The Institute for EthnoMedicine.

Planned Phase IIb Clinical Trial in ALS Patients Evaluating Adeona's Zinc-Based Therapy

Preparation of the planned Phase IIb clinical protocol is currently ongoing for submission to the Food & Drug Administration (FDA) as an addition to a current IND application. Efforts are also underway for the manufacturing of clinical trial medications and protocol review by an Institutional Review Board. The multi-center trial is intended to take place at up to six major ALS centers in the United States. It is anticipated that the trial will enroll 60 ALS patients, who will continue on RILUTEK® (riluzole) as the standard of care treatment. The patients will be randomized into treatment and matching placebo groups and will receive clinical trial medications for 12 months with periodic monitoring. The treatment group will receive Adeona's proprietary drug candidates – AEN-100, a zinc-based tab
'/>"/>

SOURCE Adeona Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Adeona Announces HartLab Expansion Into Microbiology Testing Services
2. Adeona Completes Equity Financing and Provides Alzheimers Disease Clinical Study Update
3. Adeona Announces Second Quarter 2010 Profitability and Achievements
4. Adeona Announces Five Scientific Publications on Role of Copper Toxicity and Zinc Deficiency in Alzheimers Disease and Cognitive Decline
5. Adeona CEO to Provide Keynote Address at the 2010 MichBio Expo & Conference Emerging Biosciences Showcase
6. Adeona to Hold Annual Shareholder Meeting
7. Adeona Announces Third Quarter 2010 Financial Results and Achievements
8. Adeona Acquires Access to Clinical Data Supporting Oral Zinc for Prevention of Infections in the Elderly
9. Adeona to Present at OneMedForum San Francisco 2011 Conference
10. Adeona to Host Investor Day on Zinc Deficiency in Alzheimers Disease
11. Adeona to Raise $4 Million in Registered Direct Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 22, 2014 InVivo Therapeutics Holdings Corp. (OTCQB: ... is revolutionizing spinal cord injury (SCI) treatment with their ... outperform in tissue regrowth in the spinal cord area ... an FDA approved polymer, the scaffold ultimately breaks down ... the human body. NVIV has recently attracted significant investor ...
(Date:10/22/2014)... , Oct. 22, 2014 WHEN: Wednesday, ... Online, complimentary registration available at: http://bit.ly/1yStiU9 ... Archana Vidyasekar and Visionary Innovation Research Group ... wireless electricity, self-assembling materials, nanobots and flexible ... which will transform our lives in the ...
(Date:10/22/2014)... YORK , Oct. 22, 2014 Provectus ... dermatology therapies. PV-10, its novel investigational drug for cancer, ... potential for systemic side effects. Its oncology focus is ... Provectus has completed phase 2 trials of PV-10 as ... a topical treatment for atopic dermatitis and psoriasis. ...
Breaking Medicine Technology:InVivo Therapeutics Analyst Coverage Initiated: Analyst Report by BrokerBank Securities, Inc. 2InVivo Therapeutics Analyst Coverage Initiated: Analyst Report by BrokerBank Securities, Inc. 3Futuristic Technologies That Will Transform Our World Beyond 2030 2Futuristic Technologies That Will Transform Our World Beyond 2030 3Futuristic Technologies That Will Transform Our World Beyond 2030 4Provectus Biopharmaceuticals Looks at the Asian Markets: Analyst Coverage by Small Cap Traders 2
... , BETHESDA, Md., Dec. 4 Northwest Biotherapeutics, Inc. ... that the US Patent and Trademark Office has allowed its ... stages of the manufacture of the Company,s DCVax® therapeutic cancer ... very high concentration of dendritic cells (which are the critical ...
... , RARITAN, N.J., Dec. 4 Depression, anxiety ... disorder and migraine: These are among the comorbidities reported ... had been diagnosed with epilepsy versus those without an ... households across the U.S. , Findings from " CNS-Related ...
Cached Medicine Technology:Northwest Biotherapeutics Receives Approval of US Patent for Cost Saving Automation of High-Concentration DCVax(R) Manufacturing 2Northwest Biotherapeutics Receives Approval of US Patent for Cost Saving Automation of High-Concentration DCVax(R) Manufacturing 3Northwest Biotherapeutics Receives Approval of US Patent for Cost Saving Automation of High-Concentration DCVax(R) Manufacturing 4Northwest Biotherapeutics Receives Approval of US Patent for Cost Saving Automation of High-Concentration DCVax(R) Manufacturing 5Looking Ahead to AES 2009: New Insights on Comorbidities and Other Considerations for Epilepsy Treatment 2Looking Ahead to AES 2009: New Insights on Comorbidities and Other Considerations for Epilepsy Treatment 3
(Date:10/22/2014)... TUESDAY, Oct. 21, 2014 (HealthDay News) -- The ... passengers arriving from Ebola-affected nations of West Africa ... screen them for infection with the virus. ... Jeh Johnson noted that 94 percent of air ... land at one of these five airports -- ...
(Date:10/22/2014)... 22, 2014 With the Affordable Care Act ... by the American Institutes for Research (AIR) finds that three ... use health insurance, but 42 percent say they are not ... before signing up for coverage. , The AIR survey found ... percent able to calculate correctly how much they owe for ...
(Date:10/22/2014)... 22, 2014 Losing Weight Your Body’s Way ... staring you in the face, it certainly can be difficult ... your body an extra favor by doing it the healthy ... diets. Instead, listen to your body, exercise regularly, and choose ... essential to losing weight; you need to exercise more and ...
(Date:10/22/2014)... Akeso Biomedical, Inc. , a privately held ... infections, microbial biofilms, and chronic wounds, announced that Dr. ... , Dr. Sinskey is a Professor ... of Technology, or MIT. He has been a member ... holds positions as Co-Director of the Malaysia-MIT Biotechnology Partnership ...
(Date:10/22/2014)... Tara Haelle HealthDay Reporter ... among young adult men may lead to increased blood pressure, ... cause a similar rise in blood pressure for young adult ... when young adult women drank lightly or moderately, their risk ... found. "This finding parallels studies in older adult men ...
Breaking Medicine News(10 mins):Health News:Passengers From Ebola-Affected Countries Must Land at Designated U.S. Airports 2Health News:Passengers From Ebola-Affected Countries Must Land at Designated U.S. Airports 3Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 2Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 3Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 4Health News:ReductionGuruMD Presents Ways to Improve Your Weight Loss Results 2Health News:Akeso Biomedical Appoints Dr. Anthony J. Sinskey to Board of Directors 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 3Health News:Binge Drinking May Boost Blood Pressure in Young Men 4
... Harrisburg, PA-based national dental insurer United Concordia Companies, Inc. has renamed ... Claim, to better communicate the Web-based nature of the service.The online ... , Free electronic claims ... Real-time explanations of benefits (EOBs) , ...
... AGA Medical Corporation (AGA) today,announced that, following ... the German court of appeals over Occlutech GmbH,of ... Occlutech of the,amount of damages that it will ... learning that Occlutech has terminated all manufacturing and,sales ...
... Jan. 29 A national coalition of ... other,stakeholders, has been created to help breast ... prostheses and related post-surgical items. Known ... for the Advancement, Reform,and Equity), the coalition, ...
... Medical Spa Industry Expert and CEO of Acara Medspa Consulting Group, ... 20 MedSpa Professionals from across the nation joined him for this ... ... -- 20 Top MedSpa owners, operators and managers this week attended ...
... Columbia Doctors, the Physicians and Surgeons of Columbia University select ... to medical practices and healthcare clinics, as their transcription vendor ... record. , ... Scottsdale, AZ (PRWEB) ...
... - A New Year of Growth in 2008, ... - Higher Earnings Expected , ... revenue of EUR3,074.5 million for the year ended,December 31, 2008, representing ... growth for the year was a strong 9.7%. , ...
Cached Medicine News:Health News:Speed eClaim Helps National Dental Insurer United Concordia Process Claims Quickly, Efficiently and Electronically 2Health News:AGA Medical Corporation Begins Proceedings Against Occlutech to Recover Damages 2Health News:New Coalition Created to Help Breast Cancer Survivors Gain Access to Products Designed to Improve Their Quality of Life 2Health News:20 MedSpa Professionals Gain Insight into MedSpa Business Turnaround Tactics 2Health News:Columbia Doctors, the Physicians and Surgeons of Columbia University Select MxSecure, Inc., as Their Medical Transcription Vendor of Choice 2Health News:Essilor : 2008 Revenue 2Health News:Essilor : 2008 Revenue 3Health News:Essilor : 2008 Revenue 4Health News:Essilor : 2008 Revenue 5Health News:Essilor : 2008 Revenue 6
Disposable Microscissors: Horizontal Curved Microscissors...
Sharp tipped illuminated scissors with a curvature of 12 mm to follow the contour of the retina. For cutting in the plane parallel to the retina, cutting membranes adherent to the retinal surface and...
Disposable Microscissors: Vertical, 90...
Sharp tipped scissors with a curvature of 12 mm to follow the contour of the retina. For cutting in the plane parallel to the retina, cutting membranes adherent to the retinal surface and all purpose...
Medicine Products: